A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) and Pembrolizumab in Combination with Other Investigational Agents in Subjects with High-risk Non-muscle-Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy

Brief description of study

This is a single arm, multi-site, open-label trial of pembrolizumab (MK-3475) in subjects with high risk non-muscle-invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG), who are considered ineligible for radical cystectomy or have elected not to undergo the procedure, to be conducted in conformance with Good Clinical Practices.


Clinical Study Identifier: s14-01913
ClinicalTrials.gov Identifier: NCT02625961
Principal Investigator: Scot Niglio.
Other Investigators: Victor Ricardo Adorno Febles, Laura Catherine Bauer, Hank Ng, David R. Wise.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.